---
title: "Evoke Pharma (EVOK.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/EVOK.US.md"
symbol: "EVOK.US"
name: "Evoke Pharma"
industry: "制药"
---

# Evoke Pharma (EVOK.US)

| Item | Detail |
|------|--------|
| Industry | 制药 |

## Company Profile

Evoke Pharma, Inc.是一家专注于开发和商业化治疗胃肠疾病的特种制药公司。它提供 Gimoti，这是一种用于治疗成人急性和复发性糖尿病胃轻瘫症状的美托克洛普拉胺鼻用喷雾剂。该公司将其产品营销给胃肠病专家、内科医生、初级保健医生以及特定的医疗服务提供者

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-16T04:30:14.000Z

**Overall: C (0.48)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 117 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 67.40% |  |
| Net Profit YoY | 14.98% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 14.42M |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -134.88% | E |
| Profit Margin | -36.23% | E |
| Gross Margin | 97.62% | A |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 67.40% | A |
| Net Profit YoY | 14.98% | C |
| Total Assets YoY | 10.57% | B |
| Net Assets YoY | -23.36% | E |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -276.01% | D |
| OCF YoY | 67.40% | A |

#### Operating Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.97 | A |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 78.52% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Evoke Pharma",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-134.88%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-36.23%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "97.62%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "67.40%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "14.98%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "10.57%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "-23.36%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-276.01%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "67.40%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "A",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.97",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "78.52%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 礼来 (US.LLY) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (US.RHHVF) | A | B | B | D | C | B |
| 03 | 罗氏(ADR) (US.RHHBY) | A | B | B | D | C | B |
| 04 | 阿斯利康 (US.AZN) | A | B | C | D | C | B |
| 05 | 诺华制药 (US.NVS) | A | B | C | D | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.63 | 146/256 | - | - | - |
| PB | 5.64 | 150/256 | 5.64 | 2.25 | 0.96 |
| PS (TTM) | 1.31 | 37/256 | 1.31 | 0.84 | 0.57 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-11-13T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 0 | 0% |
| Overweight | 0 | 0% |
| Hold | 1 | 100% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 11.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/EVOK.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/EVOK.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/EVOK.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.